Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Treatment of Dyspareunia with Botulinum Neurotoxin Type A: Clinical Improvement and Influence of Patients&apos, Characteristics

  • Tarazona-Motes, Marta
  • Albaladejo-Belmonte, Mónica
  • Nohales-Alfonso, Francisco J.
  • De-Arriba, Maria
  • Alberola-Rubio, Jose
  • Garcia-Casado, Javier|||0000-0003-1410-2721
[EN] The treatment of chronic pelvic pain (CPP) with botulinum neurotoxin type A (BoNT/A) has increased lately, but more studies assessing its effect are needed. This study aimed to evaluate the evolution of patients after BoNT/A infiltration and identify potential responders to treatment. Twenty-four women with CPP associated with dyspareunia were treated with 90 units of BoNT/A injected into their pelvic floor muscle (PFM). Clinical status and PFM activity were monitored in a previous visit (PV) and 12 and 24 weeks after the infiltration (W12, W24) by validated clinical questionnaires and surface electromyography (sEMG). The influence of patients' characteristics on the reduction in pain at W12 and W24 was also assessed. After treatment, pain scores and the impact of symptoms on quality of life dropped significantly, sexual function improved and sEMG signal amplitude decreased on both sides of the PFM with no adverse events. Headaches and bilateral pelvic pain were risk factors for a smaller pain improvement at W24, while lower back pain was a protective factor. Apart from reporting a significant clinical improvement of patients with CPP associated with dyspareunia after BoNT/A infiltration, this study shows that clinical characteristics should be analyzed in detail to identify potential responders to treatment., This study was funded by Universitat Politecnica de Valencia in Programa de Ayudas de Investigacion y Desarrollo (PAID-01-20), ISCIII, MCIU, VLC Campus in Convocatoria Ayudas: UPV-La Fe (INBIO): 2016 SPEHG (ID:C18), 2019 sEMG_BONTAv (ID:C06) and funds from private contracts with Merz Pharmaceuticals GmbH S.L.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Contribución de congreso (ConferenceOutput)

Influence of voluntary contractions on the basal sEMG activity of the pelvic floor muscles

  • Albaladejo-Belmonte, Monica
  • Tarazona-Motes, Marta
  • Nohales-Alfonso, Francisco J.
  • Alberola-Rubio, Jose
  • Garcia-Casado, Javier|||0000-0003-1410-2721
[EN] Chronic pelvic pain (CPP) is a complex clinical condition that affects many women, being sometimes misdiagnosed or mistreated,which can be treated with the infiltration of botulinum toxin (BoNTA). The pelvic floor musculature (PFM) condition from CPP patients can be assessed by means of surface electromyography (sEMG). The evaluation of the basal activity can help to detect a muscular dysfunction, therefore it is important to ensure that the PFM shows a minimum activation when its sEMG is being analysed. In this study, we recorded the sEMG of 25 women with CPP before and 8, 12 and 24 weeks after their treatment with BoNTA while they performed a protocol of 5 voluntary contractions. The root mean square (RMS) and sample entropy (SampEn) of basal segments pre- (B[PRE]), inter- (B[I]) and post- (B[POST]) contractions of the sEMG were computed and normalized according to the minimum (RMSnorm) and maximum (SampEnorm) of the recording. B(PRE) showed the lowest RMSnorm median both before and after the treatment with BoNTA, which proved that the activity of the PFM is minimum before the first contraction. As for SampEnnorm, although results were not so conclusive, they also indicated that B(PRE) should be taken as a reference to analyse the PFM function at its state of minimum activity. Future works aiming to characterize the effects of BoNTA in PFM by means of sEMG should consider basal segments before contractions to assess basal tone conditions., This study was funded by ISCIII, MCIU, VLC Campus in Convocatoria Ayudas: UPV-La Fe (INBIO): 2016 SPEHG (ID:C18), 2019 sEMG_BONTAv (ID:C06) and with funds from private contracts with Merz Pharma España S.L.